Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 5/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 10/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21835778 | 0.92 | HDAC2 (0.69) | HDAC2HDAC1HDAC3HPGDSGRIN2B | |
| SCHEMBL21835805 | 0.87 | HDAC2 (0.49) | HDAC2HDAC1HDAC3HPGDSBRAF | |
| SCHEMBL21835786 | 0.83 | HDAC2 (0.54) | HDAC2HDAC1HDAC3HPGDSBRAF | |
| SCHEMBL24233460 | 0.82 | HDAC2 (0.85) | HDAC2HDAC1HDAC3 | |
| SCHEMBL24233452 | 0.79 | HDAC2 (0.65) | HDAC2HDAC1HDAC3HPGDS | |
| SCHEMBL21835792 | 0.76 | MGAM (0.47) | HDAC2HPGDS | |
| SCHEMBL24233435 | 0.73 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL1068512 | 0.72 | ABL1 (0.54) | HDAC2HDAC1HDAC3 | |
| SCHEMBL4580709 | 0.72 | TDP1 (0.51) | HDAC2HDAC1HDAC3HPGDS | |
| SCHEMBL24233533 | 0.71 | HDAC2 (0.75) | HDAC2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858919-B2 | HDAC1,2 inhibitors | REGENACY PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20220033388-A1 | HDAC1,2 Inhibitors | REGENACY PHARMACEUTICALS, LLC | 2022-02-03 | — | — | US | disclosed |
| EP-3856174-A1 | HDAC1,2 INHIBITORS | Regenacy Pharmaceuticals, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020068950-A1 | HDAC1,2 INHIBITORS | REGENACY PHARMACEUTICALS, LLC (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858919-B2 | HDAC1,2 inhibitors | HDAC1, HDAC2, HDAC11 | HDAC2 2/4885HDAC1 1/4885HDAC3 6/4885 |
| US-20220033388-A1 | HDAC1,2 Inhibitors | HDAC1, HDAC2, HDAC11 | HDAC2 2/4885HDAC1 1/4885HDAC3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.